Control of Rheumatoid Arthritis (RA) by oral tolerance

Submission date	Recruitment status No longer recruiting	Prospectively registered		
18/07/2002		☐ Protocol		
Registration date 18/07/2002	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	Individual participant data		
04/10/2007	Musculoskeletal Diseases			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Ernest Choy

Contact details

Academic Department of Rheumatology GKT School of Medicines King's College Hospital (Dulwich) East Dulwich Grove London United Kingdom SE22 8PT +44 (0)20 7346 6446

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

S0523

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Rheumatoid arthritis

Interventions

Patients were randomly assigned to receive either 0.05 mg, 0.5 mg or 5 mg daily of bovine type II collagen (CII) or placebo for six months

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Bovine type II collagen

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1998

Completion date

01/01/2000

Eligibility

Key inclusion criteria

- 1. RA patients aged over 18 and fulfilling the 1987 American College of Rheumatology (ACR) criteria for the diagnosis of RA were entered into the study after giving their written informed consent.
- 2. Patients must have had the disease at least two years and have failed at least one Slow Acting Anti-Rheumatic Drug (SAARD)
- 3. All the patients had to have active arthritis defined by the presence of three out of four clinical criteria: three or more swollen joints, six or more tender joints, early morning stiffness over 45 minutes and Erythrocyte Sedimentation Rate (ESR) over 28 mm/h. Oral steroid treatment was permitted if the dose was more than 10 mg/day

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1998

Date of final enrolment

01/01/2000

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Academic Department of Rheumatology London United Kingdom **SE22 8PT**

Sponsor information

Organisation

Arthritis Research Campaign (ARC) (UK)

Sponsor details

Copeman House St Mary's Court St Mary's Gate Chesterfield Derbyshire United Kingdom S41 7TD

info@arc.org.uk

Sponsor type

Charity

Website

http://www.arc.org.uk

ROR

https://ror.org/02jkpm469

Funder(s)

Funder type

Charity

Funder Name

Arthritis Research Campaign (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/09/2001		Yes	No